carbamates has been researched along with Obesity in 18 studies
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dirlotapide is a microsomal triglyceride transfer protein (MTP) inhibitor developed specifically for canine weight reduction." | 6.44 | Dirlotapide: a review of its properties and role in the management of obesity in dogs. ( Gossellin, J; Sunderland, SJ; Wren, JA, 2007) |
| "Dirlotapide is a novel microsomal triglyceride transfer protein inhibitor intended for the treatment and management of obesity in dogs." | 5.12 | Biologic activity of dirlotapide, a novel microsomal triglyceride transfer protein inhibitor, for weight loss in obese dogs. ( Campbell, SL; Hickman, MA; King, VL; Wren, JA, 2007) |
| "Dirlotapide was evaluated in the management of obesity in dogs in two multicenter, clinical studies in North America." | 5.12 | Efficacy and safety of dirlotapide in the management of obese dogs evaluated in two placebo-controlled, masked clinical studies in North America. ( Campbell, SL; Eagleson, JS; Gossellin, J; King, VL; Ramudo, AA; Sunderland, SJ; Wren, JA, 2007) |
| " In this study, the effects of insulin glargine (IG) in combination with repaglinide or acarbose on glycemic parameters were investigated." | 2.74 | The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients. ( Duran, C; Ercan, I; Ersoy, C; Erturk, E; Guclu, M; Imamoglu, S; Kiyici, S; Selimoglu, H; Tuncel, E, 2009) |
| " Results were similar for both studies, and no serious adverse events were observed." | 2.73 | The safety of dirlotapide in dogs. ( Gossellin, J; Hickman, MA; Kerlin, RL; King, VL; Krautmann, MJ; Schmahai, TJ; Wren, JA, 2007) |
| "Dirlotapide is a microsomal triglyceride transfer protein (MTP) inhibitor developed specifically for canine weight reduction." | 2.44 | Dirlotapide: a review of its properties and role in the management of obesity in dogs. ( Gossellin, J; Sunderland, SJ; Wren, JA, 2007) |
| "Repaglinide is a suitable agent for first-line monotherapy in patients whose glucose metabolism cannot be optimally controlled by increasing physical activity and appropriate dietary measures." | 1.31 | [Antidiabetic drug at every meal. Repaglinide is especially recommended for slender type 2 diabetic patients]. ( Landgraf, R, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (22.22) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (50.00) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zeng, Z | 1 |
| Wang, L | 1 |
| Ma, W | 1 |
| Zheng, R | 1 |
| Zhang, H | 2 |
| Zeng, X | 1 |
| Zhang, W | 1 |
| Liu, J | 1 |
| Cinar, R | 1 |
| Xiong, K | 1 |
| Godlewski, G | 1 |
| Jourdan, T | 1 |
| Lin, Y | 1 |
| Ntambi, JM | 1 |
| Kunos, G | 1 |
| Zhao, S | 1 |
| Mugabo, Y | 1 |
| Ballentine, G | 1 |
| Attane, C | 1 |
| Iglesias, J | 1 |
| Poursharifi, P | 1 |
| Zhang, D | 1 |
| Nguyen, TA | 1 |
| Erb, H | 1 |
| Prentki, R | 1 |
| Peyot, ML | 1 |
| Joly, E | 1 |
| Tobin, S | 1 |
| Fulton, S | 1 |
| Brown, JM | 1 |
| Madiraju, SR | 1 |
| Prentki, M | 1 |
| Marcus, DJ | 1 |
| Zee, ML | 1 |
| Davis, BJ | 1 |
| Haskins, CP | 1 |
| Andrews, MJ | 1 |
| Amin, R | 1 |
| Henderson-Redmond, AN | 1 |
| Mackie, K | 1 |
| Czyzyk, TA | 1 |
| Morgan, DJ | 1 |
| Duran, C | 1 |
| Tuncel, E | 1 |
| Ersoy, C | 1 |
| Ercan, I | 1 |
| Selimoglu, H | 1 |
| Kiyici, S | 1 |
| Guclu, M | 1 |
| Erturk, E | 1 |
| Imamoglu, S | 1 |
| Geffner, ME | 1 |
| Patel, K | 1 |
| Miller, TL | 1 |
| Hazra, R | 1 |
| Silio, M | 1 |
| Van Dyke, RB | 1 |
| Borkowsky, W | 1 |
| Worrell, C | 1 |
| DiMeglio, LA | 1 |
| Jacobson, DL | 1 |
| SCHWARTZ, W | 1 |
| Kellerer, M | 1 |
| Jakob, S | 1 |
| Linn, T | 1 |
| Haslbeck, M | 1 |
| Li, J | 1 |
| Bronk, BS | 1 |
| Dirlam, JP | 1 |
| Blize, AE | 1 |
| Bertinato, P | 1 |
| Jaynes, BH | 1 |
| Hickman, A | 1 |
| Miskell, C | 1 |
| Pillai, UA | 1 |
| Tibbitts, JS | 1 |
| Haven, ML | 1 |
| Kolosko, NL | 1 |
| Barry, CJ | 1 |
| Manion, TB | 1 |
| Wren, JA | 5 |
| Gossellin, J | 3 |
| Sunderland, SJ | 3 |
| King, VL | 3 |
| Krautmann, MJ | 1 |
| Kerlin, RL | 1 |
| Hickman, MA | 2 |
| Schmahai, TJ | 1 |
| Campbell, SL | 2 |
| Kirk, CA | 1 |
| Boucher, JF | 1 |
| Ramudo, AA | 1 |
| Eagleson, JS | 1 |
| Landgraf, R | 1 |
| Danielsson, A | 1 |
| Bülow, M | 1 |
| Dell, HD | 1 |
| Fiedler, J | 1 |
| Kamp, R | 1 |
| Lorenz, D | 1 |
| Blickens, DA | 1 |
| Riggi, SJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adolescent Master Protocol[NCT01418014] | 678 participants (Actual) | Observational | 2007-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for carbamates and Obesity
| Article | Year |
|---|---|
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diab | 2003 |
Dirlotapide: a review of its properties and role in the management of obesity in dogs.
Topics: Animals; Anti-Obesity Agents; Carbamates; Dog Diseases; Dogs; Indoles; Obesity | 2007 |
5 trials available for carbamates and Obesity
| Article | Year |
|---|---|
The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients.
Topics: Acarbose; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; G | 2009 |
The safety of dirlotapide in dogs.
Topics: Administration, Oral; Animals; Anti-Obesity Agents; Carbamates; Dog Diseases; Dogs; Female; Indoles; | 2007 |
Biologic activity of dirlotapide, a novel microsomal triglyceride transfer protein inhibitor, for weight loss in obese dogs.
Topics: Absorptiometry, Photon; Adipose Tissue; Administration, Oral; Animals; Anti-Obesity Agents; Body Com | 2007 |
Influence of dirlotapide, a microsomal triglyceride transfer protein inhibitor, on the digestibility of a dry expanded diet in adult dogs.
Topics: Administration, Oral; Animal Feed; Animals; Anti-Obesity Agents; Carbamates; Carrier Proteins; Diet; | 2007 |
Efficacy and safety of dirlotapide in the management of obese dogs evaluated in two placebo-controlled, masked clinical studies in North America.
Topics: Administration, Oral; Animals; Anti-Obesity Agents; Carbamates; Dog Diseases; Dogs; Female; Indoles; | 2007 |
11 other studies available for carbamates and Obesity
| Article | Year |
|---|---|
Inhibiting the Notch signaling pathway suppresses Th17-associated airway hyperresponsiveness in obese asthmatic mice.
Topics: Amyloid Precursor Protein Secretases; Animals; Asthma; Carbamates; Dipeptides; Disease Models, Anima | 2019 |
Monounsaturated fatty acids generated via stearoyl CoA desaturase-1 are endogenous inhibitors of fatty acid amide hydrolase.
Topics: Amidohydrolases; Analysis of Variance; Animals; Arachidonic Acids; Benzamides; Carbamates; Endocanna | 2013 |
α/β-Hydrolase Domain 6 Deletion Induces Adipose Browning and Prevents Obesity and Type 2 Diabetes.
Topics: 3T3-L1 Cells; Adipose Tissue, Brown; Animals; Biphenyl Compounds; Carbamates; Diabetes Mellitus, Typ | 2016 |
Mice Expressing a "Hyper-Sensitive" Form of the Cannabinoid Receptor 1 (CB1) Are Neither Obese Nor Diabetic.
Topics: Amino Acid Substitution; Animals; Body Weight; Carbamates; Diabetes Mellitus, Experimental; Dose-Res | 2016 |
Factors associated with insulin resistance among children and adolescents perinatally infected with HIV-1 in the pediatric HIV/AIDS cohort study.
Topics: Adolescent; Body Mass Index; Carbamates; CD4 Lymphocyte Count; Child; Cohort Studies; Cross-Sectiona | 2011 |
MEBUTAMATE AND HYDROCHLOROTHIAZIDE IN HYPERTENSION.
Topics: Antihypertensive Agents; Arthritis; Arthritis, Rheumatoid; Blood Pressure Determination; Carbamates; | 1964 |
In vitro and in vivo profile of 5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), a novel potent MTP inhibitor for obesity.
Topics: Animals; Carbamates; Carboxylic Acids; Carrier Proteins; Chemistry, Pharmaceutical; Dogs; Drug Desig | 2007 |
[Antidiabetic drug at every meal. Repaglinide is especially recommended for slender type 2 diabetic patients].
Topics: Blood Glucose; Carbamates; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dose-Response Relationship, | 2000 |
Techniques for measuring amylase secretion from pieces of mouse pancreas.
Topics: Amylases; Animals; Carbamates; Cholecystokinin; Choline; Dinitrophenols; Epinephrine; Evaluation Stu | 1974 |
[Metabolism and distribution of chlorphentermine and clorofex in animal and man].
Topics: Adrenal Glands; Animals; Appetite Depressants; Biotransformation; Carbamates; Chlorphentermine; Dige | 1971 |
Carbohydrate metabolism in normal and hyperglycemic animals treated with 1-methyl-4-(3-methyl-5-isoxazolyl)pyridinium chloride and phenformin.
Topics: Animals; Blood Glucose; Carbamates; Carbohydrate Metabolism; Diabetes Mellitus; Diabetes Mellitus, E | 1971 |